Update: Himax Shares Soar After Q1 Results, Q2 Guidance

-- Himax Technologies (HIMX) shares were up almost 30% Thursday afternoon following its Q1 results and Q2 guidance.

Earlier, the company reported Q1 earnings of $0.046 per diluted American depositary share, down from $0.114 a year earlier.

Two analysts polled by FactSet expected $0.05 for the fabless manufacturer of display drivers and other products in Taiwan.

Revenue for the quarter ended March 31 was $199.0 million, compared with $215.1 million a year earlier.

A single analyst expected $195 million in a FactSet poll.

The company said it expects Q2 earnings of $0.09 to $0.10 per diluted ADS on net revenue growth of 10% to 13% sequentially. Two analysts expect earnings of $0.06.

Price: $15.90, Change: $+3.57, Percent Change: +28.95%

Sector Update: Consumer Stocks Edge Lower Late Afternoon

Consumer stocks were edging down late Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) each decreasing 0.1%.In corporate news, Tapestry (TPR) raised its fiscal 2026 outlook after delivering a Q3 beat, but provided a subdued Q4 sales guidance for its Kate Spade brand. Its shares dropped more than 13%.Shake Shack (SHAK) shares slumped 28% after the company's Q1 results missed Wall Street estimates.Planet Fitness (PLNT) shares tumbled 32% after the company tempered its full-year outlook amid fewer-than-expected member additions in Q1.McDonald's (MCD) reported better-than-expected Q1 results as comparable sales rebounded more than market estimates despite what the company described as a "challenging" environment. Its shares rose 0.3%.

$MCD$PLNT$SHAK$TPR

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA

Update: Himax Shares Soar After Q1 Results, Q2 Guidance

Related Articles

Sector Update: Consumer Stocks Edge Lower Late Afternoon

Sector Update: Health Care Stocks Softer Late Afternoon

Cascades Target Eased To C$13 From $14, Keeps Sector Perform at National Bk Which Notes Q1 In Line With Reduced Outlook, Soft Q2 Outlook Before Recovery, Asset Sales Done By Q3